SOURCE: Cancer Therapeutics

August 06, 2009 09:05 ET

Cancer Therapeutics Retains Capital Group Communications for Its Public Relations

SALT LAKE CITY, UT--(Marketwire - August 6, 2009) - Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today the company has retained San Francisco-based Capital Group Communications, Inc. for its public relations efforts.

Capital Group Communications, Inc. ("CGC") specializes in providing brokers, fund managers and institutions with world class investor relations for dynamic growth companies. CGC and its staff of highly respected industry leaders have over 185 combined years of finance, investor relations and Media experience. CGC believes investor relations is a highly specialized business discipline that requires expert financial and public relations knowledge. The company's due diligence employs the same criteria as major investment banking firms. Communicating effectively with the capital markets requires creativity, discipline, an understanding of legal and accounting issues and most importantly, daily interaction with the Street. Part of CGC's philosophy is that to be effective, marketing and media relations need to be in sync with broader fundamental strategic goals that support growing shareholder value.

About Cancer Therapeutics, Inc.:

Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

Contact Information

  • Contact:
    Investor Relations
    David Donlin
    Cervelle Group
    Phone: 407-614-5959 ext. 223